Traders should monitor the actual data release after the April 19 presentation for survival rate trends, which could influence investor perception of KIMMTRAK’s durability and market positioning. Positive data may support valuation, especially given the lack of competing therapies.
Price Chart
Executive Summary
Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial in metastatic uveal melanoma at the 2026 AACR Annual Meeting. This represents the longest OS follow-up in a randomized trial for this patient population, potentially reinforcing KIMMTRAK's clinical benefit in a rare and aggressive cancer with limited treatment options.
Key Facts
- Immunocore will present five-year overall survival data from the KIMMTRAK Phase 3 trial at AACR 2026.
- Data comes from a randomized trial in HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma.
- Presentation includes additional insights: subsequent treatments, treatment beyond progression, and prognostic factors.
- KIMMTRAK is already approved in the U.S., EU, Canada, Australia, and the UK for this indication.
- No financial results, revenue figures, or guidance updates were included in the release.
Financial Impact
Potential long-term commercial reinforcement of KIMMTRAK, but no immediate financial impact disclosed
Risk Factors
- Five-year OS data could show diminishing survival benefit or increased late toxicity, negatively impacting sentiment.
- No new patient enrollment or trial expansion announced; commercial uptake remains limited by HLA-A*02:01 biomarker restriction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257672 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $32.46 $32.18 | ▼ −0.86% | ▼ −0.97% | $29.71 (−8.47%) |
Aug 6, 2026 8w ago | 8-K | $34.50 $34.20 | ▼ −0.87% | ▼ −2.08% | $29.71 (−13.88%) |
May 31, 2026 17w ago | Press Release | $29.13 $28.29 | ▼ −2.88% | ▼ −0.13% | $29.71 (+1.99%) |
Apr 19, 2026 23w ago | Press Release | $31.46 $28.56 | ▼ −9.22% | ▼ −10.13% | $29.71 (−5.56%) |
Apr 8, 2026 25w ago | 144 | $31.85 $31.64 | ▼ −0.66% | ▼ −4.18% | $29.71 (−6.72%) |
Mar 17, 2026 28w ago | Press Release | $30.04 $30.28 | ▲ +0.80% | ▲ +1.51% | $29.71 (−1.10%) |
Feb 25, 2026 31w ago | 8-K | $32.16 $33.73 | ▲ +4.88% | ▲ +5.98% | $29.71 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access